Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment
Mesoblast finished patient dosing in its Phase 3 trial for a cellular back pain treatment, targeting a market worth over $10 billion.
Mesoblast finished testing a new medicine made from cells that could help people with back pain—a really big market. When a company finishes big tests, it's a sign they're getting closer to selling it, so watch if they announce good results.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.